IPO - Profile

Summary

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$21.75 20,000,000 Positive High 20.47%

Offering Team

  • Legal counsel
  • Kirkland & Ellis LLP
  • Auditors
  • Ernst & Young GmbH Wirtschaftsprfungsgesellschaft

Deal Highlights

We are an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Our mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. To that end, we have built a comprehensive suite of fully integrated, next generation technology platforms which we believe will transform the way new drugs are discovered. By leveraging the advanced capabilities of our integrated platforms, we are able to provide solutions to our partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes. Traditional drug discovery is a lengthy, costly and complex process that is subject to a high degree of uncertainty and high rates of failure. In addition, identifying novel compounds requires extensive screening and in vitro and in vivo testing, which can be both labor intensive and time-consuming. For every successful medicine that is commercialized, there are 5,000 to 10,000 compounds that fail in drug discovery. Moreover, it takes approximately 12 years of intense research and development and approximately $2 billion for a new medicine to reach patients.

Deal Tracker

IPO Dates

Filing 28 Oct, 2021

Offer 04 Nov, 2021

Look Ahead

Lock Up Expiry May 04, 2022

IPO Terms

Offer Price $21.75
Offer Size 20M

Market Sentiments

Stock Price